Abstract
The structure of the title compound, a fentanyl derivative with formula C36H36N3O3+·Cl−·2CH3OH, crystallizes as a racemic mixture. The organic cation has an extended conformation and the structure displays O–H⋯O, O–H⋯Cl and N–H⋯Cl hydrogen bonding.
Keywords: Single-crystal X-ray study, T = 173 K, Mean σ(C–C) = 0.006 Å, R factor = 0.067, wR factor = 0.231, Data-to-parameter ratio = 11.5
Comment
4-Anilidopiperidines represent the most powerful synthetic analgesics, which include fentanyl and related compounds (Janssen & Gardocki, 1964). Fentanyl is used for analgesia in clinical practice despite the fact that its use results in side effects such as respiratory depression, physical dependence and rapid tolerance (Bowdle, 1998). In order to decrease the toxicity profile of this compound we sought to replace the propionyl group of fentanyl with various α-substituted amino acids. Our biological tests showed that the characteristic high opioid activity of fentanyl can be retained if substitution of the propionyl group is done with hydrophobic amino acids. We found that the employment of l-phthaloylphenylalanyl chloride, prepared by treatment with thionyl chloride in refluxing toluene followed by coupling in the presence of triethylamine, gave us a completely racemized product, (I).

Compound (I) crystallized as a chloride salt with two molecules of methanol solvent. The structure of the cation is shown in Fig. 1. The cation has an extended conformation, with the piperidinium ring adopting a chair conformation with equatorial substituents. The size and shape of the displacement ellipsoid of C30 suggests that this atom may be disordered; a disorder model brought no improvement in refinement and so the ordered model was retained. The molecular geometry is unexceptional. N–H⋯Cl, O–H⋯Cl and O–H⋯O hydrogen bonds are found between the cation, the chloride anion and the methanol molecules (Table 1).
Figure 1.

The structure of the organic cation of (I), with 50% probability displacement ellipsoids. C-bound H atoms have been omitted.
Table 1.
Hydrogen-bond geometry (Å, °).
| D – H ⋯ A | D – H | H ⋯ A | D ⋯ A | D – H ⋯ A |
|---|---|---|---|---|
| O4–H4O⋯O5 | 0.83(1) | 2.03(4) | 2.769(6) | 148(7) |
| O5–H5O⋯Cl1 | 0.82(1) | 2.34(3) | 3.092(3) | 152(5) |
| N3–H3N⋯Cl | 0.98(4) | 2.07(4) | 3.041(4) | 170(3) |
Symmetry code: (i) x − 1, y, z.
Experimental
N-Phenyl-1-(2-phenylethyl)-4-piperidinamine (3.1 g, 11.1 mmol), prepared by the method of Maryanoff et al. (1982), and triethylamine (2.9 g, 28.9 mmol) were dissolved in dry dichloromethane (50 ml). The mixture was cooled in an ice–water bath. A solution of l-phthaloylphenylalanyl chloride (7.6 g, 24.2 mmol) in dry dichloromethane (50 ml) was added dropwise. The reaction mixture was stirred overnight. The mixture was then diluted with dichloromethane (100 ml) and washed with 5% aqueous K2CO3. The aqueous phase was extracted with dichloromethane (2 × 50 ml). The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solution was concentrated in vacuo and chromatographed with a 1:19 methanol/dichloromethane solution. The resulting compound was dissolved in anhydrous diethyl ether and precipitated by passing dry HCl through it. The resulting precipitate was filtered off and dissolved in anhydrous methanol. The product crystallized shortly after being placed in a freezer (yield 4.1 g, 59%; m.p. 479–481 K, with loss of solvent of crystallization at 427–429 K).
| Crystal data | |
| C36H36N3O3+·Cl−·2CH4O | Z = 4 |
| Mr = 658.21 | Dx = 1.237 Mg m−3 |
| Monoclinic, P21/c | Mo Kα radiation |
| a = 11.014 (2) Å | μ = 0.15 mm−1 |
| b = 17.131 (4) Å | T = 173 (2) K |
| c = 19.055 (4) Å | Block, colourless |
| β = 100.498 (7)° | 0.45 × 0.32 × 0.27 mm |
| V = 3535.3 (12) Å3 |
| Data collection | |
| Bruker SMART 1000 CCD | 4996 independent reflections |
| diffractometer | 3117 reflections with I > 2σ(I) |
| thin–slice ω scans | Rint = 0.095 |
| Absorption correction: none | θmax = 23.3° |
| 26495 measured reflections |
| Refinement | |
| Refinement on F2 | H atoms treated by a mixture of |
| R[F2 > 2σ(F2)] = 0.067 | independent and constrained |
| wR(F2) = 0.231 | refinement |
| S = 1.00 | w = 1/[σ2(Fo2) + (0.1544P)2] |
| 4996 reflections | where P = (Fo2 + 2Fc2)/3 |
| 434 parameters | (Δ/σ)max < 0.001 |
| Δρmax = 0.52 e Å−3 | |
| Δρmin = −0.56 e Å−3 |
Despite the large crystal size the data collected were very weak and essentially unobserved at higher Bragg angles. Consequently the data were truncated at a resolution of 0.9 Å. H atoms were first located in a difference map. Aromatic, CH2 and CH H atoms were refined as riding with Uiso(H) = 1.2Ueq(C) and C–H bond lengths of 0.95, 0.99 and 1.00 Å, respectively. Methyl H atoms were refined as riding with Uiso(H) = 1.5Ueq(C) and a C–H distance of 0.98 Å. O- and N-bound H atoms were refined with no constraints on geometry, giving distances as shown in Table 1, and with Uiso(H) = 1.2Ueq(O,N).
Data collection: SMART (Bruker, 2001); cell refinement: SAINT (Bruker, 2001); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2001); program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and local programs.
Acknowledgments
The work was supported by grants from the United States Public Health Service and the National Institute on Drug Abuse. The X-ray diffractometer was purchased with funds from the National Science Foundation (grant No. CHE-9610374).
References
- Bowdle TA. Drug Saf. 1998;19:173–189. doi: 10.2165/00002018-199819030-00002. [DOI] [PubMed] [Google Scholar]
- Bruker . SMART and SAINT. Bruker AXS Inc.; Madison, Wisconsin, USA: 2001. [Google Scholar]
- Janssen PAJ, Gardocki JF. US Patent 3 1418 23 1964
- Maryanoff BE, Simon EJ, Gioannini T, Gorissens HJ. J. Med. Chem. 1982;25:913–919. doi: 10.1021/jm00350a006. [DOI] [PubMed] [Google Scholar]
- Sheldrick GM. SHELXTL. Version 6. Bruker AXS Inc.; Madison, Wisconsin, USA: 2001. [Google Scholar]
